Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

L. Pagano | Gina Varricchio | F. Farina | E. Arellano | J. Labrador | M. Hoenigl | D. Hersby | C. Tascini | T. Lahmer | A. Aujayeb | A. Vena | E. D. de Kort | A. Tragiannidis | A. Busca | A. Cuccaro | J. Meletiadis | A. Guidetti | M. Gomes da Silva | N. Fracchiolla | E. Gavriilaki | J. Salmanton-García | M. Nucci | M. Criscuolo | R. Bergantim | V. Petzer | J. V. Van Praet | I. Falces-Romero | J. Prattes | M. Mikulska | C. García-Vidal | M. Merelli | C. Cattaneo | Y. Bilgin | U. Sili | M. D. del Principe | N. Coppola | F. Marchesi | G. Plantefeve | M. Biernat | I. Espigado | A. López-García | J. Hernández‐Rivas | E. Ammatuna | M. Marchetti | O. Jakšić | G. Cordini | N. Colovic | Amalia Anastasopoulou | L. Fianchi | N. Erben | M. Machado | C. Besson | S. Meers | L. Prezioso | M. Delia | R. Di Blasi | R. Duléry | F. Danion | C. Buquicchio | T. Valković | O. Finizio | A. Glenthøj | D. Wolf | H. Ommen | Z. Stojanoski | T. González‐López | L. Verga | B. Weinbergerová | O. Blennow | Antonio Giordano | J. Batinić | A. Nordlander | N. García-Poutón | Z. Emarah | L. Pinczés | N. Fernandez | C. de Ramón | M. Bonanni | G. Dragonetti | S. El-Ashwah | S. Gräfe | Ayel Yahya | M. Schönlein | T. Aiello | F. Itri | J. V. van Doesum | M. Jiménez | Irati Ormazabal-Vélez | C. De Ramón | Gustavo-Adolfo Méndez | A. Cabirta | M. Dargenio | K. Piukovics | Michail Samarkos | G. Zambrotta | M. Stamouli | M. Sacchi | G. Çolak | R. Nunes Rodrigues | J. Marques de Almeida | Sofia Zompi | J. Dávila-Valls | N. D. de Jonge | Sonia Martín-Pérez | L. Serrano | Andrés Soto-Silva | L. Rahimli | O. Cornely | Mario Virgilio Papa | Nazia Hassan | R. Córdoba | José-María Ribera-Santa Susana | Chi Shan Kho | Louis Yi Ann Chi | Matthias Eggerer | María-Josefa Jiménez-Lorenzo | Romane Prin | N. Čolović | S. Martín-Pérez | Roberta Di Blasi | Nicole García-Poutón | N. Fernández | M. Samarkos

[1]  L. Pagano,et al.  Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey , 2022, Blood.

[2]  G. Zimmermann.  Paxlovid™ jetzt direkt an Patienten abgeben , 2022, MMW - Fortschritte der Medizin.

[3]  Morgan Birabaharan,et al.  Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19 , 2022, The American Journal of Emergency Medicine.

[4]  A. Streinu-Cercel,et al.  A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019 , 2022, Open forum infectious diseases.

[5]  E. Tannous,et al.  Paxlovid-Tacrolimus Drug–Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19 , 2022, Clinical Drug Investigation.

[6]  Christina C. Chang,et al.  Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial , 2022, The Lancet Respiratory Medicine.

[7]  S. Ye,et al.  Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection , 2022, The Lancet Infectious Diseases.

[8]  Brendan R. Jackson,et al.  Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code-Level Social Vulnerability - United States, December 23, 2021-May 21, 2022. , 2022, MMWR. Morbidity and mortality weekly report.

[9]  N. Gronich,et al.  Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  H. Einsele,et al.  Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9) , 2022, Leukemia.

[11]  A. Stein,et al.  Adult patients admitted to a tertiary hospital for COVID-19 and risk factors associated with severity: a retrospective cohort study , 2022, Revista do Instituto de Medicina Tropical de Sao Paulo.

[12]  M. Baniecki,et al.  Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.

[13]  D. Day,et al.  COVID‐19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study , 2022, Asia-Pacific journal of clinical oncology.

[14]  John D. Davis,et al.  Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. , 2022, JAMA.

[15]  S. Fishbane,et al.  Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection , 2022, American Journal of Kidney Diseases.

[16]  Cameron R. Wolfe,et al.  A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus , 2021, Science Translational Medicine.

[17]  S. Madhi,et al.  COVID-19 vaccine strategies must focus on severe disease and global equity , 2021, The Lancet.

[18]  Rebecca M. Baker,et al.  Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial , 2021, The Lancet Infectious Diseases.

[19]  L. Pagano,et al.  COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA , 2021, Blood.

[20]  A. Barać,et al.  COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) , 2021, Journal of Hematology & Oncology.

[21]  L. Pagano,et al.  EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19 , 2021, HemaSphere.

[22]  D. Skovronsky,et al.  Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[23]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[24]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[25]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[26]  Elisabeth Mahase.  Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction , 2020, BMJ.

[27]  K. Sikora,et al.  Leukemia , 1984, British Journal of Cancer.

[28]  R. Evans.  European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).